One hundred and eleven patients suffering from presbyopia from both groups (Males: 63, mean Thiazovivin age: 34 +/- 14 and females: 48, mean age: 33 +/- 13 year, range: 20-60) were enrolled in the trial and divided in to two groups according to treatment regimens. Ocucure (Test drug) 500mg two tablets and leutivit (Placebo) 250mg tablets twice daily were prescribed for 6-8 weeks. Presbyopia was improved in 17 patients (28.81%) out of 59 patients by the use of ocucure (Test drug), and in 6 patients

(11.53%) out of 52 by the use of leutivit (Control drug). Furthermore, there was a significant improvement in presbyopic associated clinical features as compared to leutivit. It is concluded that ocucure possesses a therapeutic value for the improvement of presbyopia and its associated symptoms as compared to leutivit.”
“Background and objective: Community-acquired pneumonia (CAP) is generally considered to be a major cause of morbidity and mortality. There is much controversy regarding the optimal choice of antibiotics see more for patients with CAP. The aim of this study was to identify the antibiotics prescribed for adults hospitalized with CAP in Korea during a calendar year.

Methods: This population-based,

descriptive epidemiological study was performed using data from nationwide health insurance claims from 1 January 2004 to 31 December 2004. The study population was adults (>= 18 years old), who had been hospitalized with CAP as determined by discharge diagnosis, and who had been treated with antibiotics for >= 3 days. The exclusion criteria were tuberculosis, underlying malignancies and potential nosocomial pneumonia, based on the department providing care, or surgery reports during the admission.

Results: Of the 5592 adults Selleck Gilteritinib hospitalized with CAP, data for 3662 (65.5%) patients was eligible for

inclusion in the analysis. This included data for 1899 (51.9%) males, and 2045 (55.8%) patients >= 65 years of age. The most frequently prescribed antimicrobial regimen was beta-lactam/beta-lactamase inhibitors and fluoroquinolones in combination (31.0%), followed by beta-lactam/beta-lactamase inhibitors plus macrolides (30.2%), monotherapy (17.0%), beta-lactam/beta-lactamase inhibitors plus aminoglycosides (12.9%), beta-lactam/beta-lactamase inhibitors plus clindamycin (4.9%), and cephalosporins plus fluoroquinolones (2.5%). Monotherapy included, in decreasing order of use, cephalosporins (6.0%), fluoroquinolones (3.5%), beta-lactam/beta-lactamase inhibitors (2.3%) and macrolides (2.2%).

Conclusions: In this study, patterns of antimicrobial prescription for patients hospitalized with CAP were assessed for the first time in Korea. There was divergence from the 2009 Korean guidelines for the treatment of CAP, reinforcing the need for assessment of physicians’ adherence to the guidelines.